These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1174 related articles for article (PubMed ID: 25820576)
1. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion. Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576 [TBL] [Abstract][Full Text] [Related]
2. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753 [TBL] [Abstract][Full Text] [Related]
3. Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-Series. Rishi P; Raka N; Rishi E PLoS One; 2016; 11(9):e0162533. PubMed ID: 27618696 [TBL] [Abstract][Full Text] [Related]
4. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions. Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329 [TBL] [Abstract][Full Text] [Related]
5. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Shetty R; Pai SA; Vincent A; Shetty N; Narayana KM; Sinha B; Shetty BK Doc Ophthalmol; 2008 Mar; 116(2):129-35. PubMed ID: 17960440 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Kim M; Jeong S; Sagong M Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671 [TBL] [Abstract][Full Text] [Related]
7. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Ehlers JP; Decroos FC; Fekrat S Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943 [TBL] [Abstract][Full Text] [Related]
10. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH; Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042 [TBL] [Abstract][Full Text] [Related]
11. Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. Lee KH; Kang EC; Koh HJ Yonsei Med J; 2017 May; 58(3):676-678. PubMed ID: 28332380 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982 [TBL] [Abstract][Full Text] [Related]
13. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study. Bezatis A; Spital G; Höhn F; Maier M; Clemens CR; Wachtlin J; Lehmann F; Hattenbach LO; Feltgen N; Meyer CH Acta Ophthalmol; 2013 Aug; 91(5):e340-7. PubMed ID: 23638803 [TBL] [Abstract][Full Text] [Related]
14. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab. Spooner K; Fraser-Bell S; Hong T; Chang A Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion. Yang CS; Liu JH; Chung YC; Chou YB; Hung KH J Ocul Pharmacol Ther; 2015 Apr; 31(3):179-85. PubMed ID: 25715024 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916 [TBL] [Abstract][Full Text] [Related]
18. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Ahmadi AA; Chuo JY; Banashkevich A; Ma PE; Maberley DA Can J Ophthalmol; 2009 Apr; 44(2):154-9. PubMed ID: 19491948 [TBL] [Abstract][Full Text] [Related]
19. Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Thapa R; Poudyal G Nepal J Ophthalmol; 2013; 5(1):63-8. PubMed ID: 23584649 [TBL] [Abstract][Full Text] [Related]